Pure Global AI
NCT06310369Not yet recruiting

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicenter, Phase 2 Study
European Organisation for Research and Treatment of Cancer - EORTCPhase 2ClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Bladder Cancer
Drug/Device/Intervention
radiation therapy
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2025
End date
Mar 01, 2030
Enrollment
50 participants
Primary outcome

Proportion of patients with a CR at 6 months post-radiotherapy

Summary

We aim to investigate a possible role for radiotherapy in good prognosis bladder cancer
 patients has been identified as a possible alternative to cystectomy, especially for patients
 non-eligible for surgery but has yet to be fully explored.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06310369
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06310369 through Pure Global AI's free database. This Phase 2 trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.